Iradimed Corp Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Iradimed Corp has an operating margin of 30.0%, meaning the company retains $30 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is down from 30.6% the prior year.
Iradimed Corp's revenue grew 11.7% year-over-year to $73.2M, a solid pace of expansion. This earns a growth score of 62/100.
Iradimed Corp carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.84, Iradimed Corp holds $8.84 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Iradimed Corp converts 24.1% of revenue into free cash flow ($17.6M). This strong cash generation earns a score of 100/100.
Iradimed Corp earns a strong 22.1% return on equity (ROE), meaning it generates $22 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 89/100. This is down from 24.1% the prior year.
Iradimed Corp scores 69.31, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.3B) relative to total liabilities ($11.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Iradimed Corp passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Iradimed Corp generates $1.33 in operating cash flow ($25.6M OCF vs $19.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
This page shows Iradimed Corp (IRMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Iradimed Corp generated $73.2M in revenue in fiscal year 2024. This represents an increase of 11.7% from the prior year.
Iradimed Corp's EBITDA was $22.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.5% from the prior year.
Iradimed Corp generated $17.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 192.5% from the prior year.
Iradimed Corp reported $19.2M in net income in fiscal year 2024. This represents an increase of 11.9% from the prior year.
Iradimed Corp earned $1.50 per diluted share (EPS) in fiscal year 2024. This represents an increase of 11.1% from the prior year.
Iradimed Corp held $52.2M in cash against $0 in long-term debt as of fiscal year 2024.
Iradimed Corp had 13M shares outstanding in fiscal year 2024. This represents an increase of 0.4% from the prior year.
Iradimed Corp's gross margin was 76.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.
Iradimed Corp's operating margin was 30.0% in fiscal year 2024, reflecting core business profitability. This is down 0.6 percentage points from the prior year.
Iradimed Corp's net profit margin was 26.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 0.0 percentage points from the prior year.
Iradimed Corp's ROE was 22.1% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 1.9 percentage points from the prior year.
Iradimed Corp invested $2.8M in research and development in fiscal year 2024. This represents a decrease of 0.9% from the prior year.
Iradimed Corp invested $8.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 7.6% from the prior year.
IRMD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.2M+3.9% | $20.4M+4.6% | $19.5M+0.6% | $19.4M+8.1% | $17.9M+1.9% | $17.6M+0.8% | $17.5M+5.7% | $16.5M |
| Cost of Revenue | $4.7M+5.7% | $4.5M-4.6% | $4.7M+0.9% | $4.6M+18.1% | $3.9M-6.9% | $4.2M+4.2% | $4.0M+10.1% | $3.7M |
| Gross Profit | $16.5M+3.4% | $16.0M+7.5% | $14.8M+0.6% | $14.8M+5.4% | $14.0M+4.6% | $13.4M-0.2% | $13.4M+4.5% | $12.8M |
| R&D Expenses | $674K-23.1% | $877K+40.5% | $624K+9.5% | $570K-28.9% | $801K-2.4% | $821K+152.8% | -$1.6M-443.8% | $453K |
| SG&A Expenses | $4.4M+1.8% | $4.3M-7.2% | $4.6M+19.0% | $3.9M-5.6% | $4.1M+2.9% | $4.0M-6.6% | $4.3M+18.2% | $3.6M |
| Operating Income | $6.8M+0.7% | $6.8M+25.0% | $5.4M-6.4% | $5.8M+3.1% | $5.6M+18.5% | $4.7M-8.0% | $5.2M-12.6% | $5.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $1.7M+10.8% | $1.6M+23.5% | $1.3M+5.0% | $1.2M-12.5% | $1.4M+23.6% | $1.1M-3.1% | $1.1M-14.9% | $1.3M |
| Net Income | $5.6M-3.4% | $5.8M+23.2% | $4.7M-8.9% | $5.1M+5.0% | $4.9M+18.5% | $4.1M-8.9% | $4.5M-10.4% | $5.1M |
| EPS (Diluted) | $0.43-4.4% | $0.45+21.6% | $0.37-7.5% | $0.40+5.3% | $0.38+18.8% | $0.32-8.6% | $0.35-12.5% | $0.40 |
IRMD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $114.7M+7.8% | $106.4M+4.6% | $101.7M+3.5% | $98.3M+9.3% | $89.9M+2.2% | $88.0M-4.5% | $92.2M+5.4% | $87.4M |
| Current Assets | $84.9M+9.8% | $77.4M+3.0% | $75.1M-0.1% | $75.2M+2.3% | $73.6M+2.4% | $71.9M-5.4% | $76.0M+5.7% | $71.9M |
| Cash & Equivalents | $56.5M+6.7% | $53.0M+5.3% | $50.3M-3.6% | $52.2M+7.6% | $48.5M+7.6% | $45.1M-9.3% | $49.8M+6.5% | $46.7M |
| Inventory | $11.7M+4.8% | $11.2M+6.1% | $10.6M+1.5% | $10.4M-13.8% | $12.1M-4.9% | $12.7M-1.0% | $12.8M+9.9% | $11.7M |
| Accounts Receivable | $13.9M+26.9% | $10.9M-14.0% | $12.7M+20.4% | $10.6M-11.7% | $12.0M-8.2% | $13.0M+6.6% | $12.2M-4.4% | $12.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $16.4M+34.8% | $12.1M+4.0% | $11.7M+1.5% | $11.5M+12.0% | $10.3M-13.6% | $11.9M-42.6% | $20.7M+61.5% | $12.8M |
| Current Liabilities | $12.8M+45.2% | $8.8M+4.0% | $8.5M-0.5% | $8.5M+14.1% | $7.5M-2.1% | $7.6M-53.4% | $16.3M+107.1% | $7.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $98.4M+4.3% | $94.3M+4.7% | $90.1M+3.7% | $86.8M+9.0% | $79.7M+4.7% | $76.1M+6.6% | $71.4M-4.2% | $74.6M |
| Retained Earnings | $66.3M+5.4% | $62.9M+6.1% | $59.3M+4.4% | $56.8M+12.7% | $50.4M+6.3% | $47.4M+9.6% | $43.3M-7.4% | $46.7M |
IRMD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $7.0M-9.8% | $7.7M+80.5% | $4.3M-28.3% | $6.0M-9.8% | $6.6M+71.0% | $3.9M-0.7% | $3.9M+180.9% | $1.4M |
| Capital Expenditures | $1.1M-56.8% | $2.6M-28.7% | $3.7M+32.5% | $2.8M+146.0% | $1.1M+319.2% | $271K-49.1% | $532K+72.6% | $308K |
| Free Cash Flow | $5.8M+14.4% | $5.1M+759.5% | $595K-81.4% | $3.2M-41.9% | $5.5M+52.4% | $3.6M+6.9% | $3.4M+211.7% | $1.1M |
| Investing Cash Flow | -$1.3M+55.3% | -$2.8M+27.9% | -$3.9M-28.2% | -$3.1M-140.7% | -$1.3M-165.2% | -$479K+24.3% | -$633K-44.1% | -$439K |
| Financing Cash Flow | -$2.2M+2.9% | -$2.3M+0.9% | -$2.3M+5.8% | -$2.4M-23.3% | -$2.0M+75.6% | -$8.0M-2961.8% | -$263K-737.1% | -$31K |
| Dividends Paid | $2.2M0.0% | $2.2M0.0% | $2.2M+13.7% | $1.9M+0.1% | $1.9M-76.2% | $8.0M | $0 | $0 |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
IRMD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.8%-0.4pp | 78.2%+2.1pp | 76.1%-0.0pp | 76.1%-2.0pp | 78.1%+2.1pp | 76.1%-0.8pp | 76.9%-0.9pp | 77.8% |
| Operating Margin | 32.2%-1.0pp | 33.3%+5.4pp | 27.8%-2.1pp | 29.9%-1.5pp | 31.4%+4.4pp | 27.0%-2.6pp | 29.6%-6.2pp | 35.8% |
| Net Margin | 26.3%-2.0pp | 28.3%+4.3pp | 24.0%-2.5pp | 26.5%-0.8pp | 27.3%+3.8pp | 23.5%-2.5pp | 26.0%-4.7pp | 30.7% |
| Return on Equity | 5.7%-0.4pp | 6.1%+0.9pp | 5.2%-0.7pp | 5.9%-0.2pp | 6.2%+0.7pp | 5.4%-0.9pp | 6.4%-0.4pp | 6.8% |
| Return on Assets | 4.9%-0.6pp | 5.4%+0.8pp | 4.6%-0.6pp | 5.2%-0.2pp | 5.5%+0.8pp | 4.7%-0.2pp | 4.9%-0.9pp | 5.8% |
| Current Ratio | 6.64-2.1 | 8.78-0.1 | 8.87+0.0 | 8.84-1.0 | 9.87+0.4 | 9.44+4.8 | 4.65-4.5 | 9.13 |
| Debt-to-Equity | 0.17+0.0 | 0.130.0 | 0.130.0 | 0.130.0 | 0.13-0.0 | 0.16-0.1 | 0.29+0.1 | 0.17 |
| FCF Margin | 27.6%+2.5pp | 25.0%+22.0pp | 3.0%-13.4pp | 16.5%-14.2pp | 30.7%+10.2pp | 20.5%+1.2pp | 19.4%+12.8pp | 6.6% |
Similar Companies
Frequently Asked Questions
What is Iradimed Corp's annual revenue?
Iradimed Corp (IRMD) reported $73.2M in total revenue for fiscal year 2024. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Iradimed Corp's revenue growing?
Iradimed Corp (IRMD) revenue grew by 11.7% year-over-year, from $65.6M to $73.2M in fiscal year 2024.
Is Iradimed Corp profitable?
Yes, Iradimed Corp (IRMD) reported a net income of $19.2M in fiscal year 2024, with a net profit margin of 26.3%.
What is Iradimed Corp's earnings per share (EPS)?
Iradimed Corp (IRMD) reported diluted earnings per share of $1.50 for fiscal year 2024. This represents a 11.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Iradimed Corp's EBITDA?
Iradimed Corp (IRMD) had EBITDA of $22.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Iradimed Corp's gross margin?
Iradimed Corp (IRMD) had a gross margin of 76.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Iradimed Corp's operating margin?
Iradimed Corp (IRMD) had an operating margin of 30.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Iradimed Corp's net profit margin?
Iradimed Corp (IRMD) had a net profit margin of 26.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Iradimed Corp's return on equity (ROE)?
Iradimed Corp (IRMD) has a return on equity of 22.1% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Iradimed Corp's free cash flow?
Iradimed Corp (IRMD) generated $17.6M in free cash flow during fiscal year 2024. This represents a 192.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Iradimed Corp's operating cash flow?
Iradimed Corp (IRMD) generated $25.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Iradimed Corp's total assets?
Iradimed Corp (IRMD) had $98.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Iradimed Corp's capital expenditures?
Iradimed Corp (IRMD) invested $8.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Iradimed Corp spend on research and development?
Iradimed Corp (IRMD) invested $2.8M in research and development during fiscal year 2024.
How many shares does Iradimed Corp have outstanding?
Iradimed Corp (IRMD) had 13M shares outstanding as of fiscal year 2024.
What is Iradimed Corp's current ratio?
Iradimed Corp (IRMD) had a current ratio of 8.84 as of fiscal year 2024, which is generally considered healthy.
What is Iradimed Corp's debt-to-equity ratio?
Iradimed Corp (IRMD) had a debt-to-equity ratio of 0.13 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Iradimed Corp's return on assets (ROA)?
Iradimed Corp (IRMD) had a return on assets of 19.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Iradimed Corp's Altman Z-Score?
Iradimed Corp (IRMD) has an Altman Z-Score of 69.31, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Iradimed Corp's Piotroski F-Score?
Iradimed Corp (IRMD) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Iradimed Corp's earnings high quality?
Iradimed Corp (IRMD) has an earnings quality ratio of 1.33x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Iradimed Corp?
Iradimed Corp (IRMD) scores 92 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.